Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity-Reference-Cited by-同舟云学术

Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity

Published:2021-11-22 Issue:11 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Avery Jodie C¹²,Whittle Samuel L¹³,Johnston Renea V¹,Grobler Liesl¹⁴,McKenzie Bayden J¹,Cyril Sheila¹,van der Heijde Désirée⁵,Buchbinder Rachelle¹

Affiliation:

1. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology; Cabrini Health; Melbourne Australia

2. Adelaide Medical School, Robinson Research Institute; The University of Adelaide; North Adelaide Australia

3. Rheumatology Unit; Queen Elizabeth Hospital; Woodville South Australia

4. Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa

5. Department of Rheumatology; Leiden University Medical Center; Leiden Netherlands

Publisher

Wiley

Subject

Pharmacology (medical)

Reference60 articles.

1. Can we discontinue anti-TNF therapy in patients with ankylosing spondylitis and remission? A systematic literature review;Abad;Arthritis and Rheumatism,2010

2. Criteria of the classification of spondylarthropathies;Amor;Revue du Rhumatisme et des Maladies Osteo-Articulaires,1990

3. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis;Anderson;Arthritis and Rheumatism,2001

4. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis;Baeten;New England Journal of Medicine,2015

5. Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis;Brandt;Annals of the Rheumatic Diseases,2004